Investor Summary
Fund Strategy
FUND PERFORMANCE AS OF 31st December 2025
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14.0% | - | 4.0% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 4.0% | 19.0% | 12.9% | 3.2% | 34.0% | 23.7% |
| ANNUALIZED SINCE INCEPTION | QUARTERLY | YTD |
|---|---|---|
| 14.0% | - | 4.0% |
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| 4.0% | 19.0% | 12.9% | 3.2% | 34.0% | 23.7% |
Marram generated 4.0% net return in 2025, reflecting a year where market prices diverged from business performance. The portfolio maintains concentrated exposure to payment technology (15% NAV), energy infrastructure MLPs (24% NAV), large financials (17% NAV), and biopharma (9% NAV), with 35% cash for future opportunities. Payment technology holdings experienced valuation compression despite continued per-share profit growth, with PayPal, Shift4, and Paymentus showing strong fundamental progress while share prices declined. The manager rebalanced this allocation by concentrating in higher-conviction names at lower prices. Energy infrastructure remains a cornerstone given favorable demand dynamics, stable cash flows, and inflation protection. Regional bank exposure was prudently reduced after strong gains, as valuations expanded and credit standards began easing. Biopharma represents a contrarian bet on sector recovery from cyclical R&D spending lows. The strategy emphasizes patient capital deployment in businesses with durable competitive advantages trading at attractive valuations, maintaining significant cash reserves to capitalize on future dislocations.
Focus on businesses generating durable cash flows trading at attractive valuations, with emphasis on payment technology companies experiencing temporary disconnect between fundamentals and market prices, energy infrastructure assets with inflation protection, and selective opportunities in regional banks and biopharma recovery.
Manager expects payment technology investments to compound value over years through innovation and scale, with periods of market skepticism providing attractive entry points. MLPs remain cornerstone allocation given favorable industry dynamics. Biopharma positioned for recovery as capital returns to sector.
| Date | Letter | Tickers | Keywords | Pitches | Quick Takes |
|---|---|---|---|---|---|
| Jan 20 2026 | 2025 Q4 | AVDX, BILL, FITB, FOUR, OKE, PAA, PAGP, PAY, PSFE, PYPL | Banking, biopharma, cash flow, energy, payments, value | - | Payment technology businesses experiencing disconnect between operating fundamentals and share price performance. Companies continue to compound value per share despite valuation compression and shareholder turnover.… |
| Oct 20 2025 | 2025 Q3 | BPCP LN, SEI | Artificial Intelligence, Diagnostics, Growth Investing, healthcare, software |
PYPL FOUR PYPL FOUR |
The fund reports steady progress driven by healthcare and technology holdings with durable pricing power and recurring revenues. It highlights selective AI opportunities in enterprise… |
| Jul 14 2025 | 2025 Q2 | - | fundamentals, Mean reversion, Patience, valuation gaps, value | - | The letter highlights disciplined value investing amid extreme market bifurcation and speculative excess. Management argues that patience and fundamental analysis are required as valuation spreads… |
| Apr 18 2025 | 2025 Q1 | - | - | - | - |
| Jan 27 2025 | 2024 Q4 | - | - | - | - |
| Oct 20 2024 | 2024 Q3 | ENLC, PSFE | - | - | - |
| Jul 15 2024 | 2024 Q2 | - | - | - | - |
| Apr 30 2024 | 2024 Q1 | - | - | - | - |
| Jan 22 2024 | 2023 Q4 | - | - | - | - |
| Oct 23 2023 | 2023 Q3 | - | - | - | - |
| Jul 14 2023 | 2023 Q2 | - | - | - | - |
| Apr 24 2023 | 2023 Q1 | - | - | - | - |
| Jan 15 2023 | 2022 Q4 | MGI, PAYA | - | - | - |
| QUARTER | THEMES | TAGS |
|---|---|---|
| 2025 Q4 |
BiopharmaSector out of favor due to political factors leading to lower industry R&D spend. Manager believes society will continue to need new drugs and health innovations, expecting capital to return and R&D spend to reaccelerate. Initiated diversified basket allocation via ETFs and service-based businesses. |
Biotechnology Pharmaceuticals Drug Development Healthcare Innovation R&D |
EnergyEnergy plays a critical role in AI infrastructure economics, with data centers becoming major electricity consumers. Rising power costs compress margins while grid constraints and regulatory scrutiny influence deployment timelines. The manager emphasizes that unlike software-driven growth, AI compute cannot be scaled independently of physical energy reality. |
Data Centers Grid Power Infrastructure Utilities | |
PaymentsWise represents the most asymmetric investment in the portfolio, taking market share from legacy correspondent banking through cheaper, faster, and more transparent infrastructure. The company is evolving from a remittance app into a global financial services platform with three reinforcing routes to market: Consumer, Business and Platform. |
Cross-border Fintech Infrastructure Platform SME | |
Regional BanksFirst Citizens Bancshares was a contributor with solid results exceeding consensus expectations. Loans and deposits grew healthily while management continues steady share repurchases. The manager believes it's a high-quality regional bank with strong management that can unlock sustained long-term value. |
Banking Deposits Loans Buybacks Quality | |
| 2025 Q3 |
AIThe extended federal government shutdown added volatility during what was otherwise a risk-on environment, with a mid-quarter shift in market behavior for AI-related equities as the exuberant narrative evolved to one more balanced in assessing the technology's enormous potential against staggering capital spending plans and high expectations. The team initiated a position in Credo Technology as a more diversified way to gain exposure to strong trends in AI-connectivity. |
Connectivity Semiconductors Infrastructure Capital Spending |
HealthcareHealthcare was the strongest relative contributor in the quarter with holdings increasing nearly +16% compared to benchmark returns of roughly +12%. Exact Sciences was acquired for a significant premium by Abbott Laboratories resulting in an +86% return, while other strong performers included Tarsus Pharmaceuticals, Glaukos following approval of a new product, Penumbra, and Repligen driven by strong earnings results. |
M&A Product Approval Earnings Biotech | |
Technology |
||
| 2025 Q2 |
ValueThe manager continues to find attractive value opportunities despite expensive markets, purchasing undervalued companies like Centene, GlaxoSmithKline, Carrefour and PayPal trading at low multiples with strong fundamentals. |
Undervalued Low Multiples Contrarian Opportunistic |
| Date | Pitch Type | Author | Ticker | Company | Industry | Sub Industry | Bull / Bear | Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 20, 2025 | Fund Letters | Vivian Y. Chen | PYPL | PayPal Holdings Inc. | Financials | Transaction & Payment Processing Services | Bull | NASDAQ | cost discipline, digital payments, Fintech, growth, Margins, scale, valuation | Login |
| Oct 20, 2025 | Fund Letters | Vivian Y. Chen | FOUR | Shift4 Payments Inc. | Information Technology | Transaction & Payment Processing Services | Bull | NYSE | e-commerce, Fintech, hospitality, Margins, market share, Payments, valuation | Login |
| Oct 20, 2025 | Fund Letters | Vivian Y. Chen | PYPL | PayPal Holdings Inc. | Financials | Transaction & Payment Processing Services | Bull | NASDAQ | cost discipline, digital payments, Fintech, growth, Margins, scale, valuation | Login |
| Oct 20, 2025 | Fund Letters | Vivian Y. Chen | FOUR | Shift4 Payments Inc. | Information Technology | Transaction & Payment Processing Services | Bull | NYSE | e-commerce, Fintech, hospitality, Margins, market share, Payments, valuation | Login |
| TICKER | COMMENTARY |
|---|---|
| AVDX | We rebalanced this allocation by exiting positions in billing digitalization (AVDX and BILL). |
| BILL | We rebalanced this allocation by exiting positions in billing digitalization (AVDX and BILL). |
| FITB | We continued to harvest gains by trimming Fifth Third (FITB) to 6% NAV. While we remain constructive on the sector's ability to steadily generate 10%+ earnings yield, valuations have expanded, and credit underwriting standards are gradually easing. |
| FOUR | Relative weakness was also driven by Shift4 Payments |
| OKE | In November, we sold Canadian producer Cenovus (CVE), reinvesting proceeds in US midstream company ONEOK (OKE), which has underperformed recently. |
| PAA | The stock benefitted from a rotation to crude-focused companies and away from natural-gas-focused companies. |
| PAGP | We also increased our investment in Plains All American (PAA/PAGP) to 6% NAV at ~$16/share (15% cash-on-cash yield). |
| PAY | Paymentus (PAY), over the past 3 years: Revenue per share increased +85%, or +36% annualized. Free Cash Flow per share increased +204%, or +74% annualized. Share Price declined -7% over the past year. PAY currently trades at 3% free cash flow yield. |
| PSFE | The largest detractor from performance was Paysafe (United Kingdom). The online payments provider reported a weak quarter, with Digital Wallets growing more slowly than anticipated and margins in the Merchant Solutions segment coming under pressure. Given ongoing regulatory headwinds and a growth trajectory that continues to fall short of expectations, our investment team chose to exit the position. |
| PYPL | By looking at their Rnancials, FactSet, PayPal, Adobe, and Salesforce seem to be doing Rne. The market, however, is reading subdued revenue growth as a sign of increased competition on their core oSerings. These companies' outlooks look more di'cult than their past. |
| Ticker | Put/Call | Amount Bought | Shares Bought | % Change | Weight % |
|---|---|---|---|---|---|
| No Recent Buys Data | |||||
| Ticker | Put/Call | Amount Sold | Shares Sold | % Change | Weight % | Status |
|---|---|---|---|---|---|---|
| No Recent Sells Data | ||||||
| Industry | Prev Quarter % | Current Quarter % | Change |
|---|---|---|---|
| No industry data available | |||